TNNC1
Troponin C, slow skeletal and cardiac muscles
As of the edition of 20 October 2026, TNNC1 (troponin C, slow skeletal and cardiac muscles, UniProt P63316) has 2 drugs tested at it and 4 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P63316
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 61
- Disease areas
- Heart and blood vessels; Nervous system; Infections; Nutrition and metabolism; Injuries; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 65
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Levosimendan | Marketed | Phase 4 | none listed |
| TNX-103 | Active | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 1 |
| Undetermined | 3 |
| Total on the list | 4 |